Astena Holdings Co.,Ltd. (JP:8095)
:8095
Top Page
Astena Holdings Co.,Ltd.
(8095)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥499.00
▲(3.31% Upside)
Action:ReiteratedDate:01/15/26
The score is anchored by mid-level financial performance: profitability has improved in 2025, but earnings and especially free cash flow have been volatile and debt rose in 2025. Technicals are neutral-to-mildly positive, offering limited confirmation. Valuation is the main positive, supported by a low P/E and solid dividend yield.
Positive Factors
Improving gross margin and return to profitability
A sustained lift in gross margin to about 35% and a return to positive earnings in 2025 indicate stronger pricing or cost control in core distribution. Higher, more durable margins improve cash generation potential and resilience versus lower-margin peers across economic cycles.
Negative Factors
Volatile and weak free cash flow
Irregular free cash flow and thin cash conversion versus earnings constrain reinvestment, debt reduction, and dividend sustainability. Persistent working-capital swings and uneven OCF raise execution risk and reduce financial flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving gross margin and return to profitability
A sustained lift in gross margin to about 35% and a return to positive earnings in 2025 indicate stronger pricing or cost control in core distribution. Higher, more durable margins improve cash generation potential and resilience versus lower-margin peers across economic cycles.
Read all positive factors
Astena Holdings Co.,Ltd. (8095) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥19.65B
Dividend Yield3.73%
Average Volume (3M)270.46K
Price to Earnings (P/E)8.6
Beta (1Y)0.69
Revenue Growth15.00%
EPS Growth-195.87%
CountryJP
Employees1,420
SectorIndustrials
Sector Strength72
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)13.67
Shares Outstanding41,182,423
10 Day Avg. Volume280,330
30 Day Avg. Volume270,463
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.70
Price to Sales (P/S)0.30
P/FCF Ratio37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Astena Holdings Co.,Ltd. Business Overview & Revenue Model
Company Description
Astena Holdings Co., Ltd. manufactures and sells medicine-related products in Japan. The company's Fine Chemical division manufactures and sells active pharmaceutical ingredients and medical supplies for antipyretic, analgesic, anti-inflammatory, ...
How the Company Makes Money
Astena Holdings generates revenue through multiple channels, primarily by investing in and managing a diverse portfolio of businesses across its targeted sectors. The company earns income through capital appreciation and dividends from its investm...
Astena Holdings Co.,Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
56
Neutral
Cash Flow
42
Neutral
| Breakdown | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.74B | 57.99B | 51.98B | 49.64B | 72.32B |
| Gross Profit | 21.87B | 19.37B | 16.32B | 15.44B | 16.60B |
| EBITDA | 5.51B | 849.75M | 4.17B | 3.90B | 5.21B |
| Net Income | 2.19B | -2.53B | 1.16B | 579.60M | 1.74B |
Balance Sheet | |||||
| Total Assets | 75.44B | 64.60B | 67.25B | 63.55B | 63.55B |
| Cash, Cash Equivalents and Short-Term Investments | 10.19B | 6.10B | 6.88B | 6.93B | 10.93B |
| Total Debt | 22.65B | 14.99B | 16.99B | 15.05B | 15.16B |
| Total Liabilities | 48.04B | 39.29B | 38.65B | 36.48B | 36.55B |
| Stockholders Equity | 27.08B | 25.17B | 28.42B | 26.99B | 27.00B |
Cash Flow | |||||
| Free Cash Flow | 500.00M | 1.65B | -2.52B | -3.77B | -2.14B |
| Operating Cash Flow | 3.39B | 4.85B | 1.64B | -742.42M | 1.35B |
| Investing Cash Flow | -5.55B | -2.94B | -2.83B | -2.22B | -4.38B |
| Financing Cash Flow | 6.19B | -2.65B | 1.08B | -1.09B | 6.35B |
Astena Holdings Co.,Ltd. Technical Analysis
Positive
483.00
Price Trends
483.96
Positive
479.23
Positive
482.59
Positive
Market Momentum
1.25
Negative
51.72
Neutral
80.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8095, the sentiment is Positive. The current price of 483 is above the 20-day moving average (MA) of 479.80, below the 50-day MA of 483.96, and above the 200-day MA of 482.59, indicating a bullish trend. The MACD of 1.25 indicates Negative momentum. The RSI at 51.72 is Neutral, neither overbought nor oversold. The STOCH value of 80.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8095.
Astena Holdings Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥16.30B | 6.83 | ― | 2.32% | 6.60% | 27.97% | |
68 Neutral | ¥7.87B | -11.77 | ― | ― | -12.40% | 43.42% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
58 Neutral | ¥19.65B | 8.62 | ― | 3.73% | 15.00% | -195.87% | |
50 Neutral | ¥18.87B | 14.56 | ― | 1.83% | 4.30% | 52.38% | |
48 Neutral | ¥6.12B | -12.09 | ― | 2.65% | 15.66% | 56.93% | |
47 Neutral | ¥9.18B | -6.49 | ― | ― | ― | ― |
* Industrials Sector Average
JP:8095
Astena Holdings Co.,Ltd.
486.00
68.24
16.33%
JP:2796
Pharmarise Holdings Corp.
521.00
58.52
12.65%
JP:3417
Ohki Health Care Holdings, Inc.
1,368.00
662.01
93.77%
JP:4350
Medical System Network Co., Ltd.
540.00
132.67
32.57%
JP:4890
Tsubota Laboratory Incorporated
305.00
-57.00
-15.75%
JP:190A
Chordia Therapeutics Inc.
129.00
-121.00
-48.40%
Astena Holdings Co.,Ltd. Corporate Events
Astena Holdings Returns to Profit and Projects Continued Growth for FY2026
Jan 13, 2026
Astena Holdings reported consolidated net sales of ¥62.7 billion for the fiscal year ended November 30, 2025, up 8.2% year on year, with operating profit rising 7.2% to ¥3.0 billion and ordinary profit up 3.8% to ¥2.9 billion. Profi...
Astena Holdings Confirms Record-Year Dividend Payout on Strong Fine Chemicals Earnings
Jan 13, 2026
Astena Holdings has resolved to pay a year-end dividend of ¥9 per share for the fiscal year ended November 30, 2025, with a record date of November 30, 2025, subject to approval at the February 26, 2026 shareholders’ meeting. This maint...
Astena Holdings Adopts Rolling Medium-Term Plan Centered on Sustainability and Social Impact
Jan 13, 2026
Astena Holdings has updated its medium-term management plan using a rolling three-year framework starting with the fiscal year ending November 30, 2026, aiming to adjust targets annually in response to changing business conditions while pursuing i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.